---
title: "Buy Rating on First Tracks (TRAX) Driven by Strengthening IL-15/CD122 Pathway Validation and Upcoming ANB033 Clinical Catalysts in Celiac Disease and Vitiligo"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292089509.md"
description: "H.C. Wainwright analyst Emily Bodnar maintains a Buy rating on First Tracks Biotherapeutics (TRAX) with a $30 price target. The recommendation is driven by strengthened validation of the IL-15/CD122 pathway, supported by Teva's positive vitiligo data and ANB033's differentiated mechanism. Upcoming Phase 1b celiac disease results in Q4 2026 are expected to clarify competitive dynamics, supporting a favorable risk-reward profile for the stock."
datetime: "2026-07-08T13:25:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292089509.md)
  - [en](https://longbridge.com/en/news/292089509.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292089509.md)
generator: "portal-rs"
---

# Buy Rating on First Tracks (TRAX) Driven by Strengthening IL-15/CD122 Pathway Validation and Upcoming ANB033 Clinical Catalysts in Celiac Disease and Vitiligo

In a report released yesterday, Emily Bodnar from H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics Inc, with a price target of $30.00.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Emily Bodnar’s rating is based on the strengthening validation of the IL-15/CD122 pathway in immune-mediated skin and gastrointestinal diseases, highlighted by Teva’s encouraging Phase 1b vitiligo results with TEV-’408 and the mechanistic overlap with First Tracks’ lead asset ANB033. She views ANB033’s differentiated CD122 antagonism, which has shown stronger preclinical suppression of key cytotoxic T-cell activity versus competitive agents, as positioning the company well for future indications that share similar disease biology, even beyond vitiligo.

Emily Bodnar has given his Buy rating due to a combination of factors including upcoming clinical catalysts in celiac disease, where ANB033’s Phase 1b data are expected in 4Q26 and will read out alongside comparable programs such as TEV-’408 and Forte’s FB102, helping clarify competitive dynamics and the risk–benefit profile of the class. In her view, the convergence of positive external data, robust mechanistic rationale, and multiple near- to medium-term readouts in closely related indications supports a favorable risk–reward for TRAX and justifies a Buy recommendation.

### Related Stocks

- [TRAX.US](https://longbridge.com/en/quote/TRAX.US.md)
- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)
- [FBRX.US](https://longbridge.com/en/quote/FBRX.US.md)
- [34962G208.US](https://longbridge.com/en/quote/34962G208.US.md)

## Related News & Research

- [Wolfe Research Begins Coverage on First Tracks Biotherapeutics (NASDAQ:TRAX)](https://longbridge.com/en/news/296233523.md)
- [First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results](https://longbridge.com/en/news/295805215.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners | BHC Stock News](https://longbridge.com/en/news/296102688.md)
- [Is Teva Pharmaceutical Industries (TEVA) A Bargain On Its TEV 408 Phase 2b Move?](https://longbridge.com/en/news/296006711.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**